Europe Erythropoietin Drugs Market

Europe Erythropoietin Drugs Market Size (2024 to 2029)

As per the research report, the size of the Europe Erythropoietin Drugs Market was valued at USD 4.06 billion in 2024 and estimated to be growing at a CAGR of 9.5%, to reach USD 6.40 billion by 2029 during the forecast period 2024 to 2029.

The increased prevalence of chronic diseases such as CKD and cancer, both of which induce anemia, is a significant growth driver for this market.

The rise in demand for EPO medications is primarily due to cancer, End-Stage Renal Disease, and HIV. Approximately 20% of cancer/HIV patients and 70% of End-Stage Renal Disease patients get chemotherapy, which causes anemia in these patients, necessitating EPO treatment. Therefore, it is the primary source of revenue for the erythropoietin market.

Anemia is a significant driver of erythropoietin production. It is seen in the majority of cancer patients undergoing treatment. The type of chemotherapy required, the type and stage of tumor formations, and the patient's physiological characteristics influence the severity of a patient's sickness.

Severe anemia can induce weariness, weakness, and sadness in cancer patients, especially in youngsters and the elderly, lowering their quality of life. Drugs containing erythropoietin are the most effective treatment for anemia. As a result, the erythropoietin market is predicted to expand over the forecast period.

The Erythropoietin Drug Industry is a vital market driver since it is prescribed for chronic renal failure, chemotherapy, and HIV. In addition, these can also use in pharmaceutical drugs to treat low red blood cell counts during major surgical procedures.

The overwhelming demand for EPO medications is primarily due to rising cancer rates, End-Stage Renal Disease (ESRD), and HIV. Approximately 20% of cancer/HIV patients and 70% of ESRD patients get chemotherapy, which causes anemia in these patients, necessitating EPO medication. Despite this, market restrictions exist because of the high cost of EPO medications, which results in low uptake.

Another factor limiting the growth of the erythropoietin medicines market is the side effects of EPO, such as arterial hypertension, iron deficiency, and influenza-like illness, as well as the extended length of EPO treatment. The rising number of people undergoing surgery is expected to boost the market growth. People who are having surgery are at a high risk of acquiring thrombosis. It induces erythropoiesis by interacting with the erythropoietin receptor on progenitor cells in the bone marrow in a distinct way, allowing for stable and long-term anemia control.

This research report on the Europe Erythropoietin Drugs Market has been segmented and sub-segmented into the following categories

Europe Erythropoietin Drugs Market Analysis By Product

• Epoetin-alpha
• Epoetin-beta
• Darbepoetin-alfa
• Others

Europe Erythropoietin Drugs Market Analysis By Application

• Cancer
• Haematology
• Renal Diseases
• Neurology

Europe Erythropoietin Drugs Market Analysis By Drug Class

• Biologics
• Biosimilar

Europe Erythropoietin Drugs Market Analysis By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, the Europe is the second-largest contributor. The European erythropoietin Drug market is fiercely competitive with various worldwide and local marketplaces. Market competitiveness is intensified by product diversity, revenue growth, and opportunity.

During major surgical procedures, these can also use pharmaceutical drugs to treat low red blood cell counts. Epoetin alfa is human erythropoietin manufactured in cell culture using recombinant DNA technology. Epoetin alfa is prescribed to treat anemia in persons with renal disease in Europe, particularly in Germany and the United Kingdom.

A significant number of businesses are involved in the development of erythropoietin drugs. Biosimilars with improved efficacy, therapeutic impact, and cost-effectiveness are increasingly introduced. Innovative compounds are generating a growing amount of research and development. Several firms in Germany are working on finding new therapeutic areas for existing medications.

The European erythropoietin Drug market is intensely competitive, with multiple global and local marketplaces. Increased market competitiveness is fueled by product diversity, revenue growth, and opportunity.

KEY MARKET PLAYERS

Key players operating in the Europe Erythropoietin Drugs Market profiled in this report are Johnson & Johnson, Celltrion, Inc, Teva Pharmaceutical Industries Ltd. , Sun Pharmaceutical Industries Ltd. , Dr. Reddy’s Laboratories Ltd.Amgen, Inc. , F. Hoffmann-La Roche Ltd. , LG Life Sciences Ltd. , Biocon Limited  and Intas Pharmaceuticals Ltd.,